MCK

McKesson Corporation · NYSE · Healthcare · USD · 10-K for 2026, filed 2026-05-08

Figures on this page computed 2026-11-08 12:33 UTC

Last close

1,069.44USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2026, filed 2026-05-08

27.5xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2026
Accession
0000927653-26-000069
Reported in
USD
- computed
- 10-K for 2026, filed 2026-05-08
The filing itself
192.3%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2026
Accession
0000927653-26-000069
Reported in
USD
- 10-K for 2026, filed 2026-05-08
- 10-K for 2026, filed 2026-05-08
- 10-K for 2026, filed 2026-05-08
- 10-Q for 2026, filed 2026-08-05
- 10-K for 2026, filed 2026-05-08
- 10-Q for 2026, filed 2026-08-05
The filing itself
1.2%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2026
Accession
0000927653-26-000069
Reported in
USD
- 10-K for 2026, filed 2026-05-08
- 10-K for 2026, filed 2026-05-08
The filing itself
1.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2026
Accession
0000927653-26-000069
Reported in
USD
- 10-K for 2026, filed 2026-05-08
- 10-K for 2026, filed 2026-05-08
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2026
Accession
0000927653-26-000069
Reported in
USD
- 10-K for 2026, filed 2026-05-08
- 10-Q for 2026, filed 2026-08-05
The filing itself
0.3%Dividend yield
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
- computed
- computed
- computed
- computed
- Computed from the filing for 2026, filed 2026-05-08

Margins is the furthest below its sector's middle: 0.36 against 0.36 on the market's range.

What it sells, to whom

lens 8 of 9

What it sells

North American Pharmaceutical Segment336,652,000,000 USD83.7%

Oncology And Multispecialty Segment48,423,000,000 USD12.0%

Medical-Surgical Solutions Segment11,507,000,000 USD2.9%

Prescription Technology Solutions Segment5,805,000,000 USD1.4%

Where it sells it

UNITED STATES192,709,000,000 USD83.4%

International Segment38,342,000,000 USD16.6%

Each band is a share of itself. A segment and a place are two cuts of the same revenue, so they are never added together.

4 segments, 2 places and 0 named customers, each as the filer published it.

Every figure in this lens

Except where said otherwise: 10-K for 2026, filed 2026-05-08

North American Pharmaceutical Segment336,652,000,000
Source
filed
Statement
segments
Fiscal year
2026
Accession
0000927653-26-000069
Reported in
USD
The filing itself
Oncology And Multispecialty Segment48,423,000,000
Source
filed
Statement
segments
Fiscal year
2026
Accession
0000927653-26-000069
Reported in
USD
The filing itself
Medical-Surgical Solutions Segment11,507,000,000
Source
filed
Statement
segments
Fiscal year
2026
Accession
0000927653-26-000069
Reported in
USD
The filing itself
Prescription Technology Solutions Segment5,805,000,000
Source
filed
Statement
segments
Fiscal year
2026
Accession
0000927653-26-000069
Reported in
USD
The filing itself
UNITED STATES192,709,000,00010-K for 2020, filed 2020-05-22
Source
filed
Statement
revenue_mix
Fiscal year
2020
Accession
0000927653-20-000033
Reported in
USD
The filing itself
International Segment38,342,000,00010-K for 2020, filed 2020-05-22
Source
filed
Statement
revenue_mix
Fiscal year
2020
Accession
0000927653-20-000033
Reported in
USD
The filing itself